^
Association details:
| Biomarker: | TP53 mutation + KRAS mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug Class: | PD-L1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
STK11/LKB1 co-mutations to predict for de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma.
Excerpt:
Patients (pts) with metastatic KRAS-mutant LUAC who received at least one cycle of PD-1/PD-L1 therapy...in STK11/LKB1(KL) or TP53 (KP) define subgroups...Best overall response differed significantly in the KL (PR: 9.1%, SD: 15.9%, PD: 75%) and KP (PR: 33.3%, SD: 20%, PD: 46.7%) sub-groups (P = 0.005, Fisher’s exact test).
DOI:
10.1200/JCO.2017.35.15_suppl.9016
